Second, measuring PD-L1 on CD14+ cells or neutrophils alone is insufficient to determine the effectiveness of anti-PD-(L)1 treatment, since other factors such as tumor mutations and immune cell infiltration may also play significant roles in predicting treatment response. This evidence concerns the gene CD274 and neoplasm.